Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,304,391 shares of the biopharmaceutical company's stock after acquiring an additional 165,249 shares during the quarter. Nuveen Asset Management LLC owned about 1.09% of Catalyst Pharmaceuticals worth $27,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. Farther Finance Advisors LLC boosted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $65,000. KBC Group NV boosted its stake in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $104,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Analyst Ratings Changes

CPRX has been the topic of a number of recent research reports. Stephens reissued an "overweight" rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird boosted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $32.29.

Catalyst Pharmaceuticals Price Performance

CPRX traded down $0.18 during trading on Wednesday, hitting $24.66. The company's stock had a trading volume of 55,581 shares, compared to its average volume of 1,101,395. The firm's 50 day moving average price is $23.61 and its 200-day moving average price is $22.57. The stock has a market cap of $3.01 billion, a PE ratio of 20.90, a PEG ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.75 and a twelve month high of $26.16.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 351,879 shares of company stock worth $8,214,815. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.